Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;47(2):244-254.
doi: 10.1002/jimd.12714. Epub 2024 Jan 7.

Repurposing empagliflozin in individuals with glycogen storage disease Ib: A value-based healthcare approach and systematic benefit-risk assessment

Terry G J Derks  1 , Annieke Venema  1 , Clara Köller  2 , Eline Bos  1 , Ruben J Overduin  1 , Nina N Stolwijk  3 , Peter Hofbauer  4 , Mathieu S Bolhuis  5 , Fred van Eenennaam  6   7 , Henk Groen  8 , Carla E M Hollak  3   9 , Saskia B Wortmann  2   10
Affiliations

Repurposing empagliflozin in individuals with glycogen storage disease Ib: A value-based healthcare approach and systematic benefit-risk assessment

Terry G J Derks et al. J Inherit Metab Dis. 2024 Mar.

Abstract

Off-label repurposing of empagliflozin allows pathomechanism-based treatment of neutropenia/neutrophil-dysfunction in glycogen storage disease type Ib (GSDIb). From a value-based healthcare (VBHC) perspective, we here retrospectively studied patient-reported, clinical and pharmacoeconomic outcomes in 11 GSDIb individuals before and under empagliflozin at two centers (the Netherlands [NL], Austria [AT]), including a budget impact analysis, sensitivity-analysis, and systematic benefit-risk assessment. Under empagliflozin, all GSDIb individuals reported improved quality-of-life-scores. Neutrophil dysfunction related symptoms allowed either granulocyte colony-stimulating factor cessation or tapering. Calculated cost savings per patient per year ranged between € 6482-14 190 (NL) and € 1281-41 231 (AT). The budget impact analysis estimated annual total cost savings ranging between € 75 062-225 716 (NL) and € 37 697-231 790 (AT), based on conservative assumptions. The systematic benefit-risk assessment was favorable. From a VBHC perspective, empagliflozin treatment in GSDIb improved personal and clinical outcomes while saving costs, thereby creating value at multiple pillars. We emphasize the importance to reimburse empagliflozin for GSDIb individuals, further supported by the favorable systematic benefit-risk assessment. These observations in similar directions in two countries/health care systems strongly suggest that our findings can be extrapolated to other geographical areas and health care systems.

Keywords: drug repurposing; glycogen storage disease type Ib; inborn metabolic diseases; off-label treatment; rare diseases; value-based health care.

PubMed Disclaimer

References

REFERENCES

    1. Bali DS, El-Gharbawy A, Austin S, Pendyal S, Kishnani PS. Glycogen storage disease type I. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneRIews((R)). University of Washington. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993.
    1. Dale DC, Bolyard AA, Marrero T, et al. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. Curr Opin Hematol. 2019;26:16-21.
    1. www.medicijnkosten.nl. https://www.medicijnkosten.nl/medicijn?artikel=NEUPOGEN+30+INJVLST+30MIL.... Accessed August 08, 2023.
    1. Veiga-da-Cunha M, Chevalier N, Stephenne X, et al. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. Proc Natl Acad Sci U S A. 2019;116:1241-1250.
    1. Wortmann SB, Van Hove JLK, Derks TGJ, et al. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood. 2020;136:1033-1043.

Publication types

Supplementary concepts

LinkOut - more resources